PRT811
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Recurrent Glioma
Trial Timeline
Nov 6, 2019 → Mar 28, 2023
NCT ID
NCT04089449About PRT811
PRT811 is a phase 1 stage product being developed by Prelude Therapeutics for Advanced Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04089449. Target conditions include Advanced Solid Tumor, Recurrent Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04089449 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumor